Dr. Reddy’s becomes India’s second biggest drugmaker by sales
Category: #business  | By Nikita Chaurasia  | Date: 2022-11-21 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the nation’s $50 billion pharmaceutical sector in more than seven years.

As per reports, Sun Pharmaceuticals maintained its dominance as India's largest pharmaceutical company, with sales of $1.3 billion.

Dr. Reddy's, which is based in Hyderabad, posted sales of $774 million in the third quarter, while Aurobindo saw its sales decline to $701 million. Cipla, a Mumbai-based drugmaker, reported $712 million in revenue during that period.

According to an analyst at Axis Securities, sales of the generic versions of the oral cancer medication Revlimid, which made up for just over one-third of Dr. Reddy's overall business in the US, significantly benefited Dr. Reddy's and Cipla's outstanding performance.

Cipla hasn't reported any new business from the blood cancer medication. The first few pharma companies to file an application that satisfies the standards of the US drugs regulator get the lucrative 180 days of selling the medicine in the US without competition from generic rivals.

Cipla and Dr. Reddy's received the US FDA’s approval for their generic versions, following the expiration of patent for Revlimid, which was developed by Bristol Myers Squibb, last year.

Ankush Mahajan, who works as an analyst at Axis Securities, observed that although price erosion and high inflation could decrease revenue margins, Dr. Reddy’s was creating a worldwide pipeline of biosimilars and constructing novel chemical entities (NCEs) for immuno-oncology.

Mahajan further stated that the company was also creating a portfolio of nutraceuticals, vaccines, contract development and manufacturing organizations (CDMOs), and digital healthcare platforms.

Aurobindo has been suffering from low sales and falling prices for its existing formulation business in the US, which accounted for almost 46% of the total sales. The company's revenue dropped consecutively for the second time in nine months after sales fell 3.2% in January-March.

Source credit: https://www.livemint.com/companies/news/dr-reddy-s-is-now-no-2-drug-firm-as-old-order-changes-11668969242013.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...

Dubai Future Labs reveals new logistics robots in Japan at IROS 2022

Dubai Future Labs reveals new logistics robots in Japan at IROS 2022

By Nikita Chaurasia

Dubai Future Labs, Dubai Future Foundation’s applied research and development lab that focuses on robotics and artificial intelligence (AI), presented its most recent advancements to the global research and robotics community at the Internation...